Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
10/08/18
Data from TOUR™ Observational Patient Registry Demonstrate 77.1% Clinical Response Rate for VIBATIV® (telavancin) in Patients with Monomicrobial Staphylococcus aureus Infections with Vancomycin MIC ≥ 1 µg/mL Additional TOUR Data Demonstrate Unchanged Renal Function in 68.7% of Patients Who Received
10/01/18
Data from TOUR™ Patient Registry Highlight Positive Clinical Response Rates in Patients with Monomicrobial Staphylococcus aureus Infections with Vancomycin MIC ≥ 1 µg/mL Additional TOUR Data Focus on Renal Function Impact of VIBATIV Treatment for Longer than 21 Days DUBLIN , Oct.
09/25/18
DUBLIN , Sept. 25, 2018 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 , at 1:40 p.m. ET .  The conference will be held from October
09/24/18
DUBLIN , Sept. 24, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting the use of Trelegy Ellipta
09/17/18

Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®) DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Sept. 17, 2018 /PRNewswire/ --  Theravance Biopharma, Inc.

09/11/18

Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") and Mylan

08/01/18
TD-1473 Advancing into Phase 2b/3 Study in Ulcerative Colitis in Fourth Quarter Following Completion of Phase 1b Study and Successful Dialogues with FDA and EMA TD-1473 Advancing into Phase 2 Study in Crohn's Disease in Third Quarter TD-9855 Advancing into Phase 3 Program in nOH in Late 2018 or
08/01/18

Durable Improvements in nOH Symptom Severity Observed as Measured by OHSA Question #1 Findings Demonstrate Consistent Increases in Systolic Blood Pressure (SBP), Including Clinically Meaningful Improvements in Standing SBP at All Time Points Company Plans to Progress TD-9855 into Registrational

07/25/18

DUBLIN , July 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended June 30, 2018 and provide a business update before market open on Wednesday, August 1, 2018 .

05/29/18

DUBLIN , May 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that a regulatory application for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name Trelegy Ellipta has been